Jun 17 |
We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth
|
Jun 14 |
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
|
Jun 13 |
Stoke Therapeutics files to sell 10.84M shares for holders
|
Jun 3 |
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
|
May 22 |
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
|
May 8 |
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
|
May 7 |
Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
May 6 |
Analyst Expectations For Stoke Therapeutics's Future
|
May 6 |
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
|
May 6 |
Stoke Therapeutics GAAP EPS of -$0.57, revenue of $4.2M
|